Artificial intelligence company, Renalytix AI's (LON: RENX) London-listed shares are climbing on Tuesday after the company and DaVita (NYSE: DVA) revealed they will be partnering on a program aimed at slowing disease progression and improving health outcomes for the 37 million adults in the US who suffer from chronic kidney disease (CKD).
Renalytix’s shares are trading at highs of 640p, up 16.36% on the day.
The program is expected to improve patient outcomes and provide meaningful cost reductions for health care providers and payors by enabling earlier intervention for patients with early-stage kidney disease through actionable risk assessments and end-to-end care management.
The companies said they expect to launch the collaboration in three markets this year.
“Almost 50% of people whose kidneys fail find out after it is too late, and we are on a mission to change that,” said Javier Rodriguez, CEO for DaVita.
“Our partnership with RenalytixAI could allow us to help slow disease progression for the millions of people living with kidney disease,” added Rodriguez.
The program will use the KidneyIntelX in vitro diagnostic platform from RenalytixAI, which uses a machine-learning algorithm to assess a combination of biomarkers. The initial version of the KidneyIntelX risk score identifies Type 2 diabetic patients with early-stage CKD.
“This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management right to the primary care level where the majority of kidney disease patients are being seen,” said James McCullough, Renalytix’s CEO.